Neos Therapeutics Announces Appointment Of Paul Edick And John Schmid To Its Board Of Directors

DALLAS & FORT WORTH, Texas--(BUSINESS WIRE)--Neos Therapeutics, Inc. ("Neos" or "the Company"), a pharmaceutical company with three late-stage extended-release ("XR") product candidates currently in development for the treatment of attention deficit hyperactivity disorder ("ADHD"), today announced the appointment of Messrs. Paul Edick and John Schmid to its Board of Directors.

"It is with great pleasure that we welcome both Paul and John to our Board of Directors. Their extensive experience in industry-specific business and product development, strategic planning, and leadership, coupled with their financial expertise, will be extremely valuable to Neos as the Company continues to progress towards commercialization of its proprietary products," commented Alan Heller, Chairman of the Board, Neos Therapeutics.

Mr. Edick is currently the Managing Partner of 3G Advisors, LLC, a consultancy to the pharmaceutical, healthcare and investor communities. From July 2010 until November 2014, Mr. Edick was the Chief Executive Officer of Durata Therapeutics, which was acquired by Actavis plc in November 2014. Prior to that, Mr. Edick was Chief Executive Officer of Ganic Pharmaceuticals from 2008 to 2010, Chief Executive Officer of MedPointe Healthcare Inc. from 2006 to 2008, and President of Pharmaceutical Operations at MedPointe from 2002 to 2006. From 1994 to 2002, Mr. Edick worked in a series of leadership positions at G. D. Searle and its acquirer, Pharmacia Corporation. Mr. Edick currently serves on the boards of directors of NewLink Genetics Inc. and Circassia Ltd. Mr. Edick holds a B.A. in Psychology from Hamilton College in Clinton, New York.

Mr. Schmid served as Chief Financial Officer of Auspex Pharmaceuticals, Inc., from September 2013 until its sale to Teva Pharmaceuticals, Inc. in June 2015. Prior to that, he co-founded Trius Therapeutics, Inc., where he served as Chief Financial Officer from June 2004 until its merger with Cubist Pharmaceuticals, Inc. in September 2013. Mr. Schmid also served as Chief Financial Officer at GeneFormatics, Inc. from 1998 to 2003 and as Chief Financial Officer at Endonetics, Inc. from 1995 to 1998. He currently serves as chairman of the board of directors of Speak, Inc. Mr. Schmid holds a B.A. in Economics from Wesleyan University and an M.B.A. from the University of San Diego.

About Neos Therapeutics

Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platform. The Company is initially focusing on ADHD and has developed three branded product candidates that are extended-release (XR) medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. In addition, Neos manufactures and markets its generic equivalent of the branded product Tussionex®, an XR liquid suspension of hydrocodone and chlorpheniramine indicated for the relief of cough and upper respiratory symptoms of a cold.

Neos Therapeutics
Vipin K. Garg, Ph.D., 919-434-6643
President and CEO
[email protected]
or
Richard I. Eisenstadt, 972-408-1389
Chief Financial Officer
[email protected]

Suggested Articles

Loretta Itri, M.D. has been helping Immunomedics out with its troubled antibody-drug conjugate. Now, she’s signing on as its chief medical officer.

Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda.

The fund received money from Chinese organizations inside and outside the biopharma industry, enabling CICC Capital to ease past its financing goal.